Search Result

Results for "

Glucagons

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenylate Cyclase (1) Akt (5) AMPK (2) Amylin Receptor (8) Apoptosis (10) Arrestin (4) Autophagy (1) Biochemical Assay Reagents (1) CaMK (2) CGRP Receptor (1) Cytochrome P450 (2) Dipeptidyl Peptidase (27) Drug Derivative (1) Drug Intermediate (1) Endogenous Metabolite (15) Environmental Pollutants (2) ERK (11) Fluorescent Dye (5) Free Fatty Acid Receptor (1) FXR (4) G Protein-coupled Receptor Kinase (GRK) (1) GCGR (110) GLP Receptor (97) Glucocorticoid Receptor (1) Glucokinase (1) GPR119 (5) IDE (1) Insulin Receptor (8) Interleukin Related (1) Isotope-Labeled Compounds (13) mAChR (1) MEK (3) Melatonin Receptor (1) MMP (3) Na+/K+ ATPase (2) Necroptosis (4) Neuropeptide Y Receptor (1) NF-κB (2) Nuclear Hormone Receptor 4A/NR4A (4) Orphan GPCR (1) p38 MAPK (1) PACAP Receptor (2) Phosphodiesterase (PDE) (5) Phosphorylase (1) PI3K (1) PKA (15) Prostaglandin Receptor (2) PROTACs (1) Reactive Oxygen Species (ROS) (4) Reference Standards (17) Ser/Thr Protease (4) Sirtuin (1) Somatostatin Receptor (5) TGF-beta/Smad (2) TRP Channel (4)
By Research Areas:	Cancer (22) Cardiovascular Disease (14) Endocrinology (7) Inflammation/Immunology (32) Metabolic Disease (234) Neurological Disease (20)
Oligonucleotides:	Sweetening Agents (1)

267

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

128

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Retatrutide 3 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of *the glucagon* receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

Glucagon (1-29), bovine, human 10+ Cited Publications Glucagon	GCGR	Metabolic Disease Cancer
Glucagon (1-29), bovine, human, porcine is a peptide hormone, produced by pancreatic α-cells. Glucagon stimulates gluconeogenesis . Glucagon (1-29), bovine, human, porcine activates HNF4α and increases HNF4α phosphorylation .

Liraglutide 35+ Cited Publications	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

Octreotide acetate 15+ Cited Publications SMS 201-995 acetate	Somatostatin Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits growth hormone, *glucagon, and insulin* more potently.

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

Benzamidine hydrochloride 3 Publications Verification	Ser/Thr Protease	Cancer
Benzamidine hydrochloride is a competitive protease inhibitor that blocks the hydrolytic cleavage of glucagon by plasmin, trypsin and thrombin. Benzamidine hydrochloride effectively inhibits the degradation of glucagon by relevant proteases during the collection, storage and analysis of human plasma and blood samples. During in vivo metabolism, Benzamidine hydrochloride undergoes N-hydroxylation and produces multiple metabolites, exhibiting characteristics of delayed excretion or biphasic elimination. Benzamidine hydrochloride only induces slight single-strand DNA breaks at high concentrations and shows no significant genotoxic potential overall. Benzamidine hydrochloride may interfere with the detection of some glucagon antisera, but does not affect key antigen-antibody affinity at specific concentrations. Benzamidine hydrochloride can be used as a stabilizer in glucagon radioimmunoassays to ensure the accuracy and recovery rate of detection results .

Exendin-4 acetate Maximum Cited Publications 66 Publications Verification Exenatide acetate	GCGR	Cardiovascular Disease Metabolic Disease Cancer
Exendin-4 acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting *glucagon-like* peptide-1 receptor agonist with an IC₅₀ of 3.22 nM.

SRI-37330 5 Publications Verification	Arrestin	Metabolic Disease
SRI-37330 is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 can be used for type 2 diabetes research .

MK 0893 5+ Cited Publications	GCGR	Metabolic Disease
MK 0893 is a potent and selective glucagon receptor antagonist with an IC₅₀ of 6.6 nM.

Glucagon (1-29), bovine, human hydrochloride 10+ Cited Publications Glucagon hydrochloride	GCGR	Metabolic Disease Cancer
Glucagon (1-29), bovine, human, porcine hydrochloride is a peptide hormone, produced by pancreatic α-cells. Glucagon hydrochloride stimulates gluconeogenesis . Glucagon (1-29), bovine, human, porcine hydrochloride activates HNF4α and increases HNF4α phosphorylation .

Retatrutide TFA 3 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of *the glucagon* receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

LGD-6972	GCGR	Metabolic Disease
LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research .

PF-06291874 1 Publications Verification Glucagon receptor antagonists-4	GCGR	Metabolic Disease
PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM) .

Amylin, amide, human TFA DAP amide, human TFA	Amylin Receptor	Metabolic Disease
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

Exendin-4 Maximum Cited Publications 66 Publications Verification Exenatide	GCGR	Cardiovascular Disease Metabolic Disease Cancer
Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting *glucagon-like* peptide-1 receptor agonist with an IC₅₀ of 3.22 nM.

Amylin, amide, human DAP amide, human	Amylin Receptor	Metabolic Disease
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

Benzamidine 3 Publications Verification	Ser/Thr Protease	Inflammation/Immunology
Benzamidine is a competitive protease inhibitor that blocks the hydrolytic cleavage of glucagon by plasmin, trypsin and thrombin. Benzamidine effectively inhibits the degradation of glucagon by relevant proteases during the collection, storage and analysis of human plasma and blood samples. During in vivo metabolism, Benzamidine undergoes N-hydroxylation and produces multiple metabolites, exhibiting characteristics of delayed excretion or biphasic elimination. Benzamidine only induces slight single-strand DNA breaks at high concentrations and shows no significant genotoxic potential overall. Benzamidine may interfere with the detection of some glucagon antisera, but does not affect key antigen-antibody affinity at specific concentrations. Benzamidine can be used as a stabilizer in glucagon radioimmunoassays to ensure the accuracy and recovery rate of detection results .

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

Calcitonin (8-32), salmon	Amylin Receptor	Metabolic Disease
Calcitonin (8-32), salmon is a highly selective Amylin receptor antagonist. Calcitonin (8-32), salmon reverses the Amylin-mediated inhibition of glucose-induced insulin release, but has no effect on either glucagon release or somatostatin release. Calcitonin (8-32), salmon can be used for studies related to β-cell amylin .

Glucagon (19-29), human	GCGR	Neurological Disease
Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.

Dasiglucagon acetate	GCGR	Metabolic Disease
Dasiglucagon acetate is a human glucagon analog, and can increase plasma glucose. Dasiglucagon can be used in hypoglycemia research .

Glucagon (22-29)	GCGR	Metabolic Disease
Glucagon (22-29) is partial agonist of Glucagon (19–29). Glucagon specifically inhibits the Ca ²⁺ pump in liver plasma membranes independently of adenylate cyclase activation .

6bK TFA 2 Publications Verification	IDE	Metabolic Disease
6bK TFA is a selective insulin-degrading enzyme (IDE) inhibitor with an IC₅₀ of 50 nM. 6bK TFA binds to the distal pocket of IDE, thereby blocking substrate binding, peptide unfolding and cleavage processes, and reducing the degradation of insulin, glucagon and amylin. 6bK TFA improves oral glucose tolerance but impairs intraperitoneal glucose tolerance. 6bK TFA can be used in research related to type 2 diabetes .

L-168049 1 Publications Verification	GCGR	Metabolic Disease
L-168049 is a potent, selective, orally active and non-competitive glucagon receptor antagonist with IC₅₀s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively .

Glucagon-like peptide 1 (1-37), human 1 Publications Verification GLP-1 (1-37) human	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

Imapextide MBX 1416	GLP Receptor	Metabolic Disease
Imapextide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that can be used in hypoglycemia research .

GLP-1 receptor agonist 2	GCGR	Inflammation/Immunology
GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor (GLP-1R) agonist .

GRA Ex-25	GCGR	Metabolic Disease
GRA Ex-25 is an inhibitor of glucagon receptor, with IC₅₀ of 56 and 55 nM for rat and human glucagon receptors, respectively.

GCGR antagonist 2	GCGR	Metabolic Disease
GCGR antagonist 2, a Furan-2-carbohydrazide, is an orally active glucagon receptor antagonist. GCGR antagonist 2 binds to hGluR with an K_d value of 2.3 nM, and inhibits rat receptor with an IC₅₀ value of 0.43 nM. GCGR antagonist 2 inhibits glucagon-stimulated glycogenolysis .

Glucagon-like peptide 1 (1-37), human TFA 1 Publications Verification HuGLP-1 TFA	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes .

Oxyntomodulin (bovine, porcine) Glucagon-37 (bovine, porcine)	GCGR	Metabolic Disease
Oxyntomodulin (bovine, porcine), a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist .

Glucagon receptor antagonist-3	GCGR	Metabolic Disease
Glucagon receptor antagonist-3 is a highly potent glucagon receptor antagonist.

NN1177 NNC9204-1177	GCGR GLP Receptor Cytochrome P450	Metabolic Disease
NN1177 is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

Liraglutide TFA 35+ Cited Publications	GLP Receptor	Metabolic Disease
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

Gulgafafusp alfa Glutazumab; GMA-102; GMA-105	GCGR	Metabolic Disease
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R .

GLP-1 (1-36) amide (human, rat) Glucagon-like Peptide 1 (1-36) amide (human, rat)	GLP Receptor GCGR	Metabolic Disease
GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells .

*[Des-His1,Glu9]-Glucagon* amide TFA**	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the glucagon receptor, with a pA₂ of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes .

Glucagon receptor antagonist-1	GCGR	Metabolic Disease
Glucagon receptor antagonist-1 is a highly potent glucagon receptor antagonist.

Glucagon receptor antagonist-2	GCGR	Metabolic Disease
Glucagon receptor antagonist-2 is a highly potent glucagon receptor antagonist.

Benzamidine hydrochloride hydrate 3 Publications Verification Benzenecarboximidamide hydrochloride hydrate	Ser/Thr Protease	Cancer
Benzamidine (Benzenecarboximidamide) hydrochloride hydrate is a competitive protease inhibitor that blocks the hydrolytic cleavage of glucagon by plasmin, trypsin and thrombin. Benzamidine hydrochloride hydrate effectively inhibits the degradation of glucagon by relevant proteases during the collection, storage and analysis of human plasma and blood samples. During in vivo metabolism, Benzamidine hydrochloride hydrate undergoes N-hydroxylation and produces multiple metabolites, exhibiting characteristics of delayed excretion or biphasic elimination. Benzamidine hydrochloride hydrate only induces slight single-strand DNA breaks at high concentrations and shows no significant genotoxic potential overall. Benzamidine hydrochloride hydrate may interfere with the detection of some glucagon antisera, but does not affect key antigen-antibody affinity at specific concentrations. Benzamidine hydrochloride hydrate can be used as a stabilizer in glucagon radioimmunoassays to ensure the accuracy and recovery rate of detection results .

Glucagon (1-29), FAM-labeled	Fluorescent Dye	Others
Glucagon (1-29), FAM-labeled is a biological active peptide. (FAM labeled HY-P0082)

GLP-1 (1-36) amide (human, rat) TFA Glucagon-like Peptide 1 (1-36) amide (human, rat) TFA	GLP Receptor GCGR	Metabolic Disease
GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) TFA is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) TFA can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells .

*[Des-His1,Glu9]-Glucagon* amide**	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the glucagon receptor, with a pA₂ of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes .

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library

1,113 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 1,113 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Type

HY-D3172

BD-105

Fluorescent Dyes

BD-105 is a glucagon-binding fluorescent probe with a K_a value of 13.3 μM. BD-105 exhibits changes in fluorescence intensity upon interaction with glucagon, and colocalizes with glucagon in cells and tissues. BD-105 is a selective cell stain that labels glucagon-secreting cells without staining insulin-secreting cells or non-endocrine control cells. BD-105 serves as an imaging reagent for glucagon in live cells and tissues .

HY-D3173

TP-α TPG-456	Fluorescent Dyes
TP-α is a glucagon-selective two-photon fluorescent probe with a K_d of 65 μM. TP-α directly interacts with glucagon to produce significant fluorescence enhancement. TP-α selectively stains viable glucagon-secreting α cells in pancreatic islets, enabling visualization of their localization, distribution and availability. TP-α is applicable to diabetes research .

HY-D3174

PiF

Fluorescent Dyes

PiF is a fluorescent probe with high specificity for pancreatic β-cells (Ex/Em = 535 nm/565 nm), and its fluorescence signal increases significantly with elevated insulin concentrations in in vitro experiments. PiF enables visualization of rat and human islets transplanted via the portal vein in mouse livers with low liver background signals. The fluorine atom of PiF can be replaced by radioactive ¹⁸F to prepare a PET tracer. PiF can be used for research on type 1 diabetes .

Cat. No.	Product Name	Type

HY-W087937

Benzamidine hydrochloride hydrate

3 Publications Verification

Benzenecarboximidamide hydrochloride hydrate

Biochemical Assay Reagents

Benzamidine (Benzenecarboximidamide) hydrochloride hydrate is a competitive protease inhibitor that blocks the hydrolytic cleavage of glucagon by plasmin, trypsin and thrombin. Benzamidine hydrochloride hydrate effectively inhibits the degradation of glucagon by relevant proteases during the collection, storage and analysis of human plasma and blood samples. During in vivo metabolism, Benzamidine hydrochloride hydrate undergoes N-hydroxylation and produces multiple metabolites, exhibiting characteristics of delayed excretion or biphasic elimination. Benzamidine hydrochloride hydrate only induces slight single-strand DNA breaks at high concentrations and shows no significant genotoxic potential overall. Benzamidine hydrochloride hydrate may interfere with the detection of some glucagon antisera, but does not affect key antigen-antibody affinity at specific concentrations. Benzamidine hydrochloride hydrate can be used as a stabilizer in glucagon radioimmunoassays to ensure the accuracy and recovery rate of detection results .

Cat. No.	Product Name	Target	Research Area

HY-P3506

Retatrutide 3 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of *the glucagon* receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P0082

Glucagon (1-29), bovine, human 10+ Cited Publications Glucagon	GCGR	Metabolic Disease Cancer
Glucagon (1-29), bovine, human, porcine is a peptide hormone, produced by pancreatic α-cells. Glucagon stimulates gluconeogenesis . Glucagon (1-29), bovine, human, porcine activates HNF4α and increases HNF4α phosphorylation .

HY-P0014

Liraglutide 35+ Cited Publications	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P0264

Exendin(9-39) amide 30+ Cited Publications Avexitide	GLP Receptor	Metabolic Disease
Exendin(9-39) amide (Avexitide) is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for binding to GLP-1 receptors, thereby antagonizing the effects of excess GLP-1 secretion. Exendin(9-39) amide can be used to study postoperative hypoglycemia (PBH) .

HY-17365

Octreotide acetate 15+ Cited Publications SMS 201-995 acetate	Somatostatin Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits growth hormone, *glucagon, and insulin* more potently.

HY-P0120

Dulaglutide 1 Publications Verification LY2189265	GCGR	Metabolic Disease
Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-13443A

Exendin-4 acetate Maximum Cited Publications 66 Publications Verification Exenatide acetate	GCGR	Cardiovascular Disease Metabolic Disease Cancer
Exendin-4 acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting *glucagon-like* peptide-1 receptor agonist with an IC₅₀ of 3.22 nM.

HY-P1393

AC 187	Amylin Receptor	Endocrinology
AC 187 is a potent and orally active amylin receptor antagonist with an IC₅₀ of 0.48 nM and a K_i of 0.275 nM. AC 187 shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 has neuroprotective effects .

HY-P0082A

Glucagon (1-29), bovine, human hydrochloride 10+ Cited Publications Glucagon hydrochloride	GCGR	Metabolic Disease Cancer
Glucagon (1-29), bovine, human, porcine hydrochloride is a peptide hormone, produced by pancreatic α-cells. Glucagon hydrochloride stimulates gluconeogenesis . Glucagon (1-29), bovine, human, porcine hydrochloride activates HNF4α and increases HNF4α phosphorylation .

HY-P3366

Ecnoglutide XW003	GCGR	Metabolic Disease
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity .

HY-P3506A

Retatrutide TFA 3 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of *the glucagon* receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-P1141

GLP-1(9-36)amide	GCGR	Metabolic Disease
GLP-1(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic GLP-1 receptor .

HY-P1070A

Amylin, amide, human TFA DAP amide, human TFA	Amylin Receptor	Metabolic Disease
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-13443

Exendin-4 Maximum Cited Publications 66 Publications Verification Exenatide	GCGR	Cardiovascular Disease Metabolic Disease Cancer
Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting *glucagon-like* peptide-1 receptor agonist with an IC₅₀ of 3.22 nM.

HY-P1070

Amylin, amide, human DAP amide, human	Amylin Receptor	Metabolic Disease
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

HY-P1782

Calcitonin (8-32), salmon	Amylin Receptor	Metabolic Disease
Calcitonin (8-32), salmon is a highly selective Amylin receptor antagonist. Calcitonin (8-32), salmon reverses the Amylin-mediated inhibition of glucose-induced insulin release, but has no effect on either glucagon release or somatostatin release. Calcitonin (8-32), salmon can be used for studies related to β-cell amylin .

HY-P0150

Glucagon (19-29), human	GCGR	Neurological Disease
Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.

HY-P3469A

Dasiglucagon acetate	GCGR	Metabolic Disease
Dasiglucagon acetate is a human glucagon analog, and can increase plasma glucose. Dasiglucagon can be used in hypoglycemia research .

HY-P3617

Glucagon (22-29)	GCGR	Metabolic Disease
Glucagon (22-29) is partial agonist of Glucagon (19–29). Glucagon specifically inhibits the Ca ²⁺ pump in liver plasma membranes independently of adenylate cyclase activation .

HY-P1145

Glucagon-like peptide 1 (1-37), human 1 Publications Verification GLP-1 (1-37) human	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P10957

Imapextide MBX 1416	GLP Receptor	Metabolic Disease
Imapextide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that can be used in hypoglycemia research .

HY-P11271

Ribupatide	Insulin Receptor GLP Receptor	Metabolic Disease
Ribupatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .

HY-P2535

GLP-1 (7-36), amide, biotin labeled GLP-1 (7-36)-Lys(biotin)-amide	GLP Receptor	Metabolic Disease
Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human is an C-terminal-labelled biotinylated GLP-1 (7-36) amide.

HY-P10929

Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH	Drug Intermediate	Others
Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH is a drug intermediate in the synthesis of Tirzepatide. Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor (GLP-1R) agonist .

HY-P4796

Oxyntomodulin (human, mouse, rat) Proglucagon (33-69)	Peptides	Metabolic Disease
Oxyntomodulin (human, mouse, rat) (Proglucagon (33-69)) is a product of the glucagon precursor. Oxyntomodulin (human, mouse, rat) contains the entire glucagon sequence plus a C-terminal octapeptide, comprising in total 37 amino acids.

HY-P1145A

Glucagon-like peptide 1 (1-37), human TFA 1 Publications Verification HuGLP-1 TFA	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes .

HY-P1144

Oxyntomodulin (bovine, porcine) Glucagon-37 (bovine, porcine)	GCGR	Metabolic Disease
Oxyntomodulin (bovine, porcine), a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist .

HY-P0165

Taspoglutide ITM077; R1583; BIM51077	GCGR	Metabolic Disease
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC₅₀ value of 0.06 nM.

HY-P10271

RG7697 NNC0090-2746; MAR709; RO6811135	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA	Isotope-Labeled Compounds GLP Receptor GCGR	Others
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10032

NN1177 NNC9204-1177	GCGR GLP Receptor Cytochrome P450	Metabolic Disease
NN1177 is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-P0014B

Liraglutide TFA 35+ Cited Publications	GLP Receptor	Metabolic Disease
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

HY-P5815

GLP-1 (1-36) amide (human, rat) Glucagon-like Peptide 1 (1-36) amide (human, rat)	GLP Receptor GCGR	Metabolic Disease
GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells .

HY-P10269

Bofanglutide GZR18	GLP Receptor	Metabolic Disease
Bofanglutide (GZR18) is an analog of glucagon-like peptide-1 (GLP-1), which exhibits agonistic activity for GLP-1 receptor, with an EC₅₀ of 0.677 nM. GZR18 ameliorates type 2 diabetes .

HY-P1393A

AC 187 TFA	Amylin Receptor	Endocrinology
AC 187 TFA is a potent and orally active amylin receptor antagonist with an IC₅₀ of 0.48 nM and a K_i of 0.275 nM. AC 187 TFA shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 TFA has neuroprotective effects .

HY-P1348

GLP-1 moiety from Dulaglutide [Gly8,36,Glu22]-GLP-1 (7-37)	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide. GLP-1 moiety from Dulaglutide is a glucagon-like peptide 1 receptor (GLP-1) agonist. Dulaglitude can be used in researches of diabetes and myocardial injury .

HY-106103

Seglitide MK-678; L-363586	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes .

HY-P0264A

Exendin(9-39) amide acetate 30+ Cited Publications Avexitide acetate	GLP Receptor	Metabolic Disease
Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research .

HY-P1143A

*[Des-His1,Glu9]-Glucagon* amide TFA**	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the glucagon receptor, with a pA₂ of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes .

HY-P0082F

Glucagon (1-29), FAM-labeled	Fluorescent Dye	Others
Glucagon (1-29), FAM-labeled is a biological active peptide. (FAM labeled HY-P0082)

HY-P5815A

GLP-1 (1-36) amide (human, rat) TFA Glucagon-like Peptide 1 (1-36) amide (human, rat) TFA	GLP Receptor GCGR	Metabolic Disease
GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) TFA is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) TFA can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells .

HY-P2497

Exendin (5-39) 1 Publications Verification	GCGR	Neurological Disease
Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats .

HY-P1141A

GLP-1(9-36)amide TFA	GCGR	Metabolic Disease
GLP-1(9-36)amide TFA is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic GLP-1 receptor .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P1143

*[Des-His1,Glu9]-Glucagon* amide**	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the glucagon receptor, with a pA₂ of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99357

Crotedumab REGN1193; Anti-GCGR Reference Antibody (crotedumab)	GCGR	Metabolic Disease
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a K_D of 0.1 nM. Crotedumab can be used for the research of diabetes .

HY-P99383

Volagidemab REMD-477; AMG-477	GCGR	Metabolic Disease
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .

HY-P990013

Gulgafafusp alfa Glutazumab; GMA-102; GMA-105	GCGR	Metabolic Disease
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R .

HY-P992007

PF-06293620 RN909	GCGR	Metabolic Disease
PF-06293620 (RN909) is a monoclonal antibody antagonist of the glucagon receptor. PF-06293620 produces dose-dependent, durable lowering of fasting plasma glucose and reduces HbA1c levels. PF-06293620 can be used for the research of type 2 diabetes mellitus .

HY-P992006

*Anti-Glucagon* Antibody**	GCGR	Inflammation/Immunology
Anti-Glucagon Antibody is an anti-Glucagon antibody. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Cat. No.	Product Name	Chemical Structure

HY-P0014S1

Liraglutide-13C5,15N tetraTFA
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-13749AS

Sitagliptin-d4 phosphate

Sitagliptin-d₄ phosphate (MK-0431-d₄) is the deuterium labeled Sitagliptin phosphate (HY-13749A). Sitagliptin phosphate is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes.

HY-13749S1

Sitagliptin-d4 hydrochloride

Sitagliptin-d₄ hydrochloride is the deuterium labeled Sitagliptin hydrochloride (HY-13749E). Sitagliptin hydrochloride is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin hydrochloride blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin hydrochloride can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin hydrochloride shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin hydrochloride can be used for the study of 1-type and 2-type diabetes.

HY-P0014AS

Liraglutide-d8 tetraTFA
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P1624S1

Teduglutide-Leu(13C6,15N) sodium

Teduglutide-Leu( ¹³C₆, ¹⁵N) (ALX-0600-Leu( ¹³C₆, ¹⁵N)) sodium is the ¹³C- and ¹⁵N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-P0014S2

Liraglutide-13C6,15N TFA
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-13443S

Exendin-4 (Leu-13C6,15N) TFA
Exendin-4 (Leu- ¹³C₆, ¹⁵N) (Exenatide (Leu- ¹³C₆, ¹⁵N)) TFA is the ¹³C- and ¹⁵N-labeled Exendin-4 TFA (HY-13443). Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC₅₀ of 3.22 nM .

HY-W014839S

Cyclamic acid-d11 sodium

Cyclamic acid-d₁₁ (Sodium cyclamate-d₁₁) sodiumis deuterium labeled Cyclamic acid (sodium). Cyclamic acid sodium (Sodium cyclamate) is a commonly used sweetener. Cyclamic acid sodium is toxic to osteoblasts and can inhibit cell proliferation, induce apoptosis and reduce cell mineralization. Cyclamic acid sodium causes focal necrosis of bladder organs in rats in vitro, which can promote bladder cancer, but some studies have shown that low doses of Cyclamic acid sodium have no carcinogenic effect. In addition, Cyclamic acid sodium has no effect on insulin and glucagon secretion induced by arginine .

HY-W014839S1

Cyclamic acid-d4 sodium

Cyclamic acid-d₄ (Sodium cyclamate-d₄) sodium is the deuterium labeled Cyclamic acid sodium (HY-W014839). Cyclamic acid sodium (Sodium cyclamate) is a commonly used sweetener. Cyclamic acid sodium is toxic to osteoblasts and can inhibit cell proliferation, induce apoptosis and reduce cell mineralization. Cyclamic acid sodium causes focal necrosis of bladder organs in rats in vitro, which can promote bladder cancer, but some studies have shown that low doses of Cyclamic acid sodium have no carcinogenic effect. In addition, Cyclamic acid sodium has no effect on insulin and glucagon secretion induced by arginine .

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA

Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis .

HY-13749S3

Sitagliptin-d6

Sitagliptin-d₆ (MK-0431-d₆) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.

HY-P1624S

Teduglutide-Ala(13C3,15N) sodium

Teduglutide-Ala( ¹³C₃, ¹⁵N) (ALX-0600-Ala( ¹³C₃, ¹⁵N)) sodium is the ¹³C- and ¹⁵N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-13749S2

Sitagliptin-d4

Sitagliptin-d₄ (MK-0431-d₄) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.

HY-W701772

2-Oleoylglycerol-d5

2-Oleoylglycerol-d₅ (2-OG-d₅) is the deuterium labeled 2-Oleoylglycerol (HY-W011121). 2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC₅₀ value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .

Cat. No.	Product Name		Classification

HY-W014839

Cyclamic acid sodium Sodium cyclamate; Cyclohexylsulfamic acid sodium		Sweetening Agents
Cyclamic acid sodium (Sodium cyclamate) is a commonly used sweetener. Cyclamic acid sodium is toxic to osteoblasts and can inhibit cell proliferation, induce apoptosis and reduce cell mineralization. Cyclamic acid sodium causes focal necrosis of bladder organs in rats in vitro, which can promote bladder cancer, but some studies have shown that low doses of Cyclamic acid sodium have no carcinogenic effect. In addition, Cyclamic acid sodium has no effect on insulin and glucagon secretion induced by arginine .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Glucagons

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products